Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. (Q39917828)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. |
scientific article |
Statements
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model (English)
Maria Virginia C L Appleyard
Mary A O'Neill
Karen E Murray
Fiona E M Paulin
Susan E Bray
Neil M Kernohan
David A Levison
Alastair M Thompson
1 January 2009
1 reference